Understand this story
Story summary
The English summary is being updated. See the reporting timeline below.
Developments
1 confirmed developments
- Source:English text is being prepared.
Reports and discussion timeline
Browse reports and discussion by time. Their evidence levels remain distinct.
Nov 18
Securities Times
Jitai Technology Begins Preparations for A-Share Listing as Commercialization of AI Drug Delivery Accelerates
Jitai Technology has begun preparations for an A-share listing and engaged a pre-listing advisory firm, but has yet to finalize a supporting plan or submit a formal application. Revenue in the first half of this year reached RMB 154 million, up 13,399% year on year, while its adjusted net loss narrowed by 56.4% to RMB 51 million. The company has also recently entered into partnerships with Eli Lilly, JOINN Laboratories and Hengrui Pharma to advance the commercialization of LNP and mRNA drugs and the AiTEM platform.
AI Trends